# JS207 Combination Therapy in Triple-negative Breast Cancer

Source: https://onco.cc/trials/nct07045311/  
OnCo record `nct07045311` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Shanghai Junshi Bioscience Co., Ltd., now recruiting.

## Summary

JS207 Combination Therapy in Triple-negative Breast Cancer is a phase 2, interventional study registered as NCT07045311 by Shanghai Junshi Bioscience Co., Ltd., with a registry enrolment figure of 80 participants, started 2025-09-17 and due to reach its primary completion in 2028-03-22. Interventions recorded: JS207 in combination with 9MW2821; JS207 in combination with Albumin paclitaxel. Conditions listed: Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: "Histologically confirmed unresectable, locally advanced or metastatic triple-negative breast cancer(absence of HER2, ER, and PR expression);". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07045311
- Phase: 2
- Setting: JS207 Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
- Sponsor: Shanghai Junshi Bioscience Co., Ltd.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07045311: https://clinicaltrials.gov/study/NCT07045311

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07045311.json